Search

Displaying results 7041 - 7050 of 7555 in total
  1. Drug

    Dazdotuftide

    go.drugbank.com/drugs/DB21550
    Investigational

    Dazdotuftide is under investigation in clinical trial NCT05042609 (A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma).

  2. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

  3. Drug

    TMC-649128

    go.drugbank.com/drugs/DB15152
    Investigational

    TMC-649128 is under investigation in clinical trial NCT01391117 (TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics

  4. Drug

    Indium In-111 chloride

    go.drugbank.com/drugs/DB09490
    Approved

    It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI.

  5. Drug

    Cetrelimab

    go.drugbank.com/drugs/DB15421
    Investigational

    Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD

  6. Drug

    Brofaromine

    go.drugbank.com/drugs/DB13876
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    2,5-Dimethoxy-4-ethylthioamphetamine

    go.drugbank.com/drugs/DB13940
    Experimental

    2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Rozrolimupab

    go.drugbank.com/drugs/DB05209
    Investigational

    Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic

  9. Drug

    AVX-001

    go.drugbank.com/drugs/DB19194
    Investigational

    AVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult

  10. Drug

    SW033291

    go.drugbank.com/drugs/DB32765
    Experimental

    [A275473, A275474] It has been found to increase prostaglandin E2 (PGE2) and is being investigated in accelerating of hematopoietic recovery and treating type 2 diabetes mellitus.[A275473, A275474]